Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Monte Rosa Therapeutics Inc
(NQ:
GLUE
)
6.330
+0.700 (+12.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monte Rosa Therapeutics Inc
< Previous
1
2
3
4
Next >
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 16, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 15, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
May 02, 2024
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 26, 2024
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 26, 2024
Via
Benzinga
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
March 14, 2024
GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
February 15, 2024
Wedbush initiates coverage on Monte Rosa Therapeutics. With differentiated lead programs and AI-driven QuEEN platform, the company shows strong potential for value creation.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
January 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Via
The Motley Fool
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
January 10, 2024
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
January 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 13, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.